Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Elicio Therapeutics, Inc.
Next earnings ≈ Jul 10, 2026 · est. from filing cadence
Last earnings +17.2% on 2026-05-11
Revenue fell -91.9% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Elicio Therapeutics, Inc. shows $2.30M in FY2022 revenue (-91.9% YoY), a -1719.7% net margin, and -2418.8% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001601485, latest 10-Q filed 2026-05-11) · EODHD · rules-based read · as of 6/18/2026, 2:02:40 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $28.3M | $2.30M | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| Net income | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Diluted EPS | -$1.93 | -$89.27 | -$6.96 | -$4.25 | -$2.58 |
| Net margin | -192.8% | -1225.9% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2026-02-02 | Connelly Robert CEO, President and Director | Award | 73.6K | |
| 2026-02-02 | Shah Preetam See Remarks | Award | 24.0K | |
| 2026-02-02 | DeMuth Peter Chief Scientific Officer | Award | 20.8K | |
| 2026-02-02 | Haqq Christopher See Remarks | Award | 25.4K | |
| 2025-12-09 | DeMuth Peter Chief Scientific Officer | Exercise | 362.00 @ $4.41 | $1.60K |